Olaparib stopped prostate cancer growth, generating falls in prostate specific antigen (PSA) levels, falls in circulating tumour cell counts in the blood, and radiological responses on CT scans and MRI.
Not exact matches
He is currently leading the TOPARP trial, which is finding out whether a drug called
olaparib (Lynparza) improves survival for men with advanced prostate cancer that has
stopped responding to treatment.